TY - JOUR AU - Croft, S. L. AU - Duparc, S. AU - Arbe-Barnes, S. J. AU - Craft, J. C. AU - Shin, C. S. AU - Fleckenstein, L. PY - 2012 DA - 2012// TI - Review of pyronaridineanti-malarial properties and product characteristics JO - Malar J VL - 11 UR - https://doi.org/10.1186/1475-2875-11-270 DO - 10.1186/1475-2875-11-270 ID - Croft2012 ER - TY - JOUR AU - Tshefu, A. K. AU - Gaye, O. AU - Kayentao, K. AU - Thompson, R. AU - Bhatt, K. M. AU - Sesay, S. S. PY - 2010 DA - 2010// TI - Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial JO - Lancet VL - 375 UR - https://doi.org/10.1016/S0140-6736(10)60322-4 DO - 10.1016/S0140-6736(10)60322-4 ID - Tshefu2010 ER - TY - JOUR AU - Kayentao, K. AU - Doumbo, O. K. AU - Pénali, L. K. AU - Offianan, A. T. AU - Bhatt, K. M. AU - Kimani, J. PY - 2012 DA - 2012// TI - Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial JO - Malar J VL - 11 UR - https://doi.org/10.1186/1475-2875-11-364 DO - 10.1186/1475-2875-11-364 ID - Kayentao2012 ER - TY - JOUR AU - Rueangweerayu, R. AU - Phyo, A. P. AU - Uthaisin, C. AU - Poravuth, Y. AU - Binh, T. Q. AU - Tinto, H. PY - 2012 DA - 2012// TI - Pyronaridine–artesunate versus mefloquine plus artesunate for malaria JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1007125 DO - 10.1056/NEJMoa1007125 ID - Rueangweerayu2012 ER - TY - JOUR AU - Poravuth, Y. AU - Socheat, D. AU - Rueangweerayut, R. AU - Uthaisin, C. AU - Pyae Phyo, A. AU - Valecha, N. PY - 2011 DA - 2011// TI - Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial JO - PLoS One VL - 6 UR - https://doi.org/10.1371/journal.pone.0014501 DO - 10.1371/journal.pone.0014501 ID - Poravuth2011 ER - TY - JOUR AU - Dondorp, A. M. AU - Nosten, F. AU - Yi, P. AU - Das, D. AU - Phyo, A. P. AU - Tarning, J. PY - 2009 DA - 2009// TI - Artemisinin resistance in Plasmodium falciparum malaria JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0808859 DO - 10.1056/NEJMoa0808859 ID - Dondorp2009 ER - TY - JOUR AU - Ashley, E. A. AU - Dhorda, M. AU - Fairhurst, R. M. AU - Amaratunga, C. AU - Lim, P. AU - Suon, S. PY - 2015 DA - 2015// TI - Spread of artemisinin resistance in Plasmodium falciparum malaria JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1314981 DO - 10.1056/NEJMoa1314981 ID - Ashley2015 ER - TY - JOUR AU - Leang, R. AU - Taylor, W. R. J. AU - MeyBouth, D. AU - Song, L. AU - Tarning, J. AU - Chuor Char, M. PY - 2015 DA - 2015// TI - Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: Dihydroartemisinin-piperaquine open-label multicentre clinical assessment JO - Antimicrob Agents Chemother VL - 59 UR - https://doi.org/10.1128/AAC.00835-15 DO - 10.1128/AAC.00835-15 ID - Leang2015 ER - TY - JOUR AU - Spring, M. AU - Lin, J. T. AU - Manning, J. E. AU - Vanachayangkul, P. AU - Somethy, S. AU - Bun, R. PY - 2015 DA - 2015// TI - Dihydroartemisinin-piperaquine failure associated with a triple mutant including Kelch13 C580Y in Cambodia: an observational cohort study JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)70049-6 DO - 10.1016/S1473-3099(15)70049-6 ID - Spring2015 ER - TY - JOUR AU - Pascual, A. AU - Madamet, M. AU - Briolant, S. AU - Gaillard, T. AU - Amalvict, R. AU - Benoit, N. PY - 2015 DA - 2015// TI - Multinormalin vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine JO - Malar J VL - 14 UR - https://doi.org/10.1186/s12936-015-0586-6 DO - 10.1186/s12936-015-0586-6 ID - Pascual2015 ER - TY - JOUR AU - Pascual, A. AU - Parola, P. AU - Benoit-Vical, F. AU - Simon, F. AU - Malvy, D. AU - Picot, S. PY - 2012 DA - 2012// TI - Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum JO - Malar J VL - 11 UR - https://doi.org/10.1186/1475-2875-11-45 DO - 10.1186/1475-2875-11-45 ID - Pascual2012 ER - TY - JOUR AU - Price, R. N. AU - Marfurt, J. AU - Chalfein, F. AU - Kenagalem, E. AU - Piera, K. A. AU - Tjitra, E. PY - 2010 DA - 2010// TI - In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparumand Plasmodium vivax JO - Antimicrob Agents Chemother VL - 54 UR - https://doi.org/10.1128/AAC.00801-10 DO - 10.1128/AAC.00801-10 ID - Price2010 ER - TY - JOUR AU - Briolant, S. AU - Henry, M. AU - Oeuvray, C. AU - Amalvict, R. AU - Baret, E. AU - Didillon, E. PY - 2010 DA - 2010// TI - Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum JO - Antimicrob Agents Chemother VL - 54 UR - https://doi.org/10.1128/AAC.00183-10 DO - 10.1128/AAC.00183-10 ID - Briolant2010 ER - TY - JOUR AU - Pascual, A. AU - Madamet, M. AU - Bertaux, L. AU - Amalvict, R. AU - Benoit, N. AU - Travers, D. PY - 2013 DA - 2013// TI - In vitropiperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene JO - Malar J VL - 12 UR - https://doi.org/10.1186/1475-2875-12-431 DO - 10.1186/1475-2875-12-431 ID - Pascual2013 ER - TY - JOUR AU - Pradines, B. AU - Briolant, S. AU - Henry, M. AU - Oeuvray, C. AU - Baret, E. AU - Amalvict, R. PY - 2010 DA - 2010// TI - Absence of association between pyronaridinein vitro responses and polymorphisms involved in quinoline resistance in Plasmodium falciparum JO - Malar J VL - 9 UR - https://doi.org/10.1186/1475-2875-9-339 DO - 10.1186/1475-2875-9-339 ID - Pradines2010 ER - TY - JOUR AU - Okombo, J. AU - Kiara, S. M. AU - Mwai, L. AU - Pole, L. AU - Ohuma, E. AU - Ochola, L. I. PY - 2012 DA - 2012// TI - Baseline In vitro activities of the antimalarialspyronaridine and methylene blue against Plasmodium falciparum isolates from Kenya JO - Antimicrob Agents Chemother VL - 56 UR - https://doi.org/10.1128/AAC.05454-11 DO - 10.1128/AAC.05454-11 ID - Okombo2012 ER - TY - JOUR AU - Mwai, L. AU - Kiara, S. M. AU - Abdirahman, A. AU - Pole, L. AU - Rippert, A. AU - Diriye, A. PY - 2009 DA - 2009// TI - In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1 JO - Antimicrob Agents Chemother VL - 55 UR - https://doi.org/10.1128/AAC.00638-09 DO - 10.1128/AAC.00638-09 ID - Mwai2009 ER - TY - JOUR AU - Hao, M. AU - Jia, D. AU - Li, Q. AU - He, Y. AU - Yuan, L. AU - Xu, S. PY - 2013 DA - 2013// TI - In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to Piperaquine and association with polymorphisms in candidate genes JO - Antimicrob Agents Chemother VL - 57 UR - https://doi.org/10.1128/AAC.02306-12 DO - 10.1128/AAC.02306-12 ID - Hao2013 ER - TY - JOUR AU - Okombo, J. AU - Abdi, A. I. AU - Kiara, S. M. AU - Mwai, L. AU - Pole, L. AU - Sutherland, C. J. PY - 2013 DA - 2013// TI - Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses JO - Antimicrob Agents Chemother VL - 57 UR - https://doi.org/10.1128/AAC.01465-13 DO - 10.1128/AAC.01465-13 ID - Okombo2013 ER - TY - JOUR AU - Henrich, P. P. AU - O'Brien, C. AU - Sáenz, F. E. AU - Cremers, S. AU - Kyle, D. E. AU - Fidock, D. A. PY - 2014 DA - 2014// TI - Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model JO - Antimicrob Agents Chemother VL - 58 UR - https://doi.org/10.1128/AAC.01466-13 DO - 10.1128/AAC.01466-13 ID - Henrich2014 ER - TY - JOUR AU - Sagara, I. AU - Beavogui, A. H. AU - Zongo, I. AU - Soulama, I. AU - Borghini-Fuhrer, I. AU - Fofana, B. PY - 2015 DA - 2015// TI - Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial JO - Lancet Infect Dis ID - Sagara2015 ER -